Inhibrx ROCE
¿Qué es el ROCE de Inhibrx?
El ROCE de Inhibrx, Inc. es 758.45%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en NASDAQ en comparadas con Inhibrx
¿Qué hace Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas con roce similar a Inhibrx
- Molecular Data Inc tiene ROCE de 682.69%
- 9 Meters Biopharma tiene ROCE de 684.23%
- Biosig Technologies Inc tiene ROCE de 689.29%
- BioCardia tiene ROCE de 724.72%
- Elfato tiene ROCE de 731.09%
- ContraFect Corp tiene ROCE de 754.78%
- Inhibrx tiene ROCE de 758.45%
- Corvus Gold tiene ROCE de 760.11%
- Havn Life Sciences Inc tiene ROCE de 763.04%
- Sabine Royalty Trust tiene ROCE de 785.68%
- Winners tiene ROCE de 793.33%
- American Environmental tiene ROCE de 831.71%
- Killi tiene ROCE de 837.33%